FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

The US Food and Drug Administration (FDA) granted historic approval to daraxonrasib (Rasonque), establishing it as a first-in-class targeted therapy for the most common form of pancreatic cancer. Specifically indicated for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic treatment, this daily oral medication was approved several months ahead of schedule. The decision brings a highly anticipated, chemotherapy-free targeted option to a patient population historically limited by a lack of effective therapeutic interventions.

According to the National Cancer Institute, pancreatic adenocarcinoma accounts for approximately 90% to 95% of the 67,000 new pancreatic cancer cases diagnosed in the United States annually. Despite representing roughly 3.2% of all cancer diagnoses, it is responsible for a disproportionately high share of overall cancer deaths. This disparity is largely driven by typically late detection, an aggressive disease course, and a historical shortage of targeted therapies.

Addressing this high unmet need, daraxonrasib represents a novel pharmacological class. It is a once-daily oral tablet therapy that acts as a multi-form RAS inhibitor. The drug is engineered to target multiple forms of the RAS protein, which acts as a key molecular driver of tumor growth in most patients with pancreatic adenocarcinoma. By directly binding to and inhibiting these aberrant proteins, daraxonrasib blocks downstream signaling pathways that promote malignant cellular proliferation and survival.

The clinical efficacy supporting this approval was demonstrated in a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. In this study, daraxonrasib demonstrated unprecedented clinical benefit, doubling median overall survival to 13.2 months compared to just 6.7 months for patients receiving standard chemotherapy.

Reflecting on the study's impact, Angelo de Claro, MD, director of the FDA's Oncology Center of Excellence, noted in a news release that daraxonrasib "showed unprecedented results in an area of high unmet need." Additionally, de Claro emphasized that the approval was granted 6.5 months before the user fee deadline, illustrating the agency's commitment to accelerating access to therapeutic innovations for life-threatening conditions.

To expedite its clinical availability, the FDA granted daraxonrasib Breakthrough Therapy and Orphan Drug designations, alongside a Priority Review. The application was also reviewed under the Commissioner's National Priority Voucher pilot program, designed to accelerate therapies addressing public health priorities.

For oncology nurses, the approval of daraxonrasib introduces vital clinical management responsibilities, particularly regarding patient education and proactive toxicity monitoring. Because daraxonrasib is an oral agent taken at home, nursing-led assessment of adherence and side-effect management is paramount to ensure treatment continuation and maximize quality of life.

The most common adverse reactions identified during clinical testing of daraxonrasib include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. Oncology nurses must play an active role in managing these symptoms:

• Rash: Educate patients on daily skin care, including the use of alcohol-free emollients and sunscreen, and monitor for early signs of dermatological toxicity.
• Diarrhea and Nausea: Establish clear self-care protocols. Instruct patients to maintain hydration and begin prescribed antiemetic or antidiarrheal therapies at the first sign of gastrointestinal distress.
• Stomatitis: Instruct patients to perform regular oral assessments, use soft-bristled toothbrushes, and avoid irritating foods.
• Fatigue and Edema: Work with patients to balance physical activity with rest, and monitor for peripheral swelling or rapid weight gain.

Additionally, oncology nurses must remain informed about expanded access protocols. In May, the FDA issued a "safe to proceed" letter allowing the manufacturer, Revolution Medicines, Inc., to initiate an expanded access treatment protocol. This allowed many eligible patients to access daraxonrasib prior to formal approval. Nurses should guide patients and families on continuing access pathways and facilitate the transition from expanded access programs to commercial drug distribution.

References

1. FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer. FDA News Release. Silver Spring, MD: US Food and Drug Administration; August 26, 2026. Accessed August 26, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer